VERAXA Biotech AG (NASDAQ: VRXA) announced new in vitro proof-of-concept data supporting its novel BiTAC-ADC technology platform, designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells and achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components.
VERAXA said the findings further validate the potential of its BiTAC-ADC platform and complement its BiTAC-TCE technology, providing the company with two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. The company plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026. To view the full press release, visit https://ibn.fm/QiPhH.
The BiTAC-ADC platform represents a significant advancement in antibody-drug conjugate technology. By using two separate precursor components that only become active when combined at the tumor site, the approach aims to reduce systemic toxicity often associated with traditional ADCs. This tumor-restricted activation could potentially expand the therapeutic window for potent cytotoxic agents, making them safer for patients.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond.
The company's news and updates are available in its newsroom at http://ibn.fm/VRXA. The latest developments in the biotechnology, biomedical sciences and life sciences sectors are covered by BioMedWire, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN. BioMedWire delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release distribution, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions.
